News &amp; Updates

Better maternal cardiovascular health during pregnancy is associated with a lower risk of developmental delay in offspring, whereas poor maternal cardiovascular health during pregnancy contributes to a risk increase, according to a study.

Maternal cardiovascular health during pregnancy affects offspring development

Original New Drug Application Approvals by US FDA (16-30 June 2026)

New drug applications approved by US FDA as of 16-30 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2026)

Hepatic steatosis increases non-calcified plaque burden

Hepatic steatosis may raise the risk of major adverse cardiovascular events through increased non-calcified plaque burden, according to a study.

Hepatic steatosis increases non-calcified plaque burden

Dysphagia a red flag for poor outcomes after cardiovascular procedures

Among individuals undergoing common cardiovascular procedures, those with a preoperative diagnosis of dysphagia face an increased risk of postoperative mortality and complications, according to a retrospective study.

Dysphagia a red flag for poor outcomes after cardiovascular procedures

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

Treatment with camrelizumab combined with apatinib demonstrates improvements in overall survival (OS), progression-free survival (PFS), and response rates in patients with esophageal squamous cell carcinoma (ESCC), a study has shown.

Camrelizumab plus apatinib shows promising safety, efficacy in ESCC

Oral paclitaxel on par with IV formulation in HER2-negative breast cancer

A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.

Oral paclitaxel on par with IV formulation in HER2-negative breast cancer

08 Jul 2026

More complications, readmissions seen in RCC patients with comorbidities

Renal cell carcinoma (RCC) patients with comorbidities are at greater risk for postoperative kidney and urinary complications and readmissions, reports a study, noting the importance of comorbidity management in surgical care in this population.

More complications, readmissions seen in RCC patients with comorbidities

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).

MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM

08 Jul 2026

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Engaging in resistance training over midlife and limiting sedentary behaviour have been shown to substantially lower the risk of type 2 diabetes (T2D) in a study.

Consistent resistance training, limited sedentary behaviour help lower T2D risk

Selinexor-ruxolitinib combo improves SVR in patients with JAKi-naïve myelofibrosis

In patients with Janus kinase inhibitor (JAKi)-naïve myelofibrosis, the addition of selinexor to ruxolitinib significantly improves the incidence of spleen volume reduction of ≥35 percent (SVR35) compared with ruxolitinib alone, according to the SENTRY trial presented at ASCO 2026.

Selinexor-ruxolitinib combo improves SVR in patients with JAKi-naïve myelofibrosis